165 related articles for article (PubMed ID: 19930971)
21. Epigenetics in the hematologic malignancies.
Fong CY; Morison J; Dawson MA
Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A; Zhou H; Yang J; Li M; Niu T
Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.
Kinoshita T
Int J Hematol; 2004 Aug; 80(2):108-19. PubMed ID: 15481438
[TBL] [Abstract][Full Text] [Related]
24. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
25. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
26. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic changes in solid and hematopoietic tumors.
Toyota M; Issa JP
Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
[TBL] [Abstract][Full Text] [Related]
28. Targeting aberrant chromatin structure in colorectal carcinomas.
Konishi K; Issa JP
Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
30. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
31. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments.
Schnekenburger M; Florean C; Dicato M; Diederich M
Curr Top Med Chem; 2016; 16(7):745-76. PubMed ID: 26303418
[TBL] [Abstract][Full Text] [Related]
33. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.
Fraga MF; Berdasco M; Ballestar E; Ropero S; Lopez-Nieva P; Lopez-Serra L; Martín-Subero JI; Calasanz MJ; Lopez de Silanes I; Setien F; Casado S; Fernandez AF; Siebert R; Stifani S; Esteller M
Cancer Res; 2008 Jun; 68(11):4116-22. PubMed ID: 18519670
[TBL] [Abstract][Full Text] [Related]
36. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
Sun C; Duan P; Luan C
Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
[TBL] [Abstract][Full Text] [Related]
37. Epigenetically-targeted therapies for the treatment of hematological malignancies.
Georgiou E; Kouidou S
Curr Med Chem; 2011; 18(12):1757-64. PubMed ID: 21466475
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
39. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
40. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
